Molecular Diagonstics Market: Current Scenario and Forecast (2019-2025): Emphasis on Product (Reagents, Instruments Services), Techniques (Polymerase Chain Reaction (PCR), Transcription-Mediated Amplification (TMA), In Situ Hybridization, DNA Sequencing & Next-Generation Sequencing (NGS), Chips and Microarrays, Others), Application (Microbiology, Virology, Hospital Acquired Infections (HAI), Genetic Testing, Oncology, Pharmacogenetics, Human Leukocytes Antigen (HLA), Blood Screening, Others), End-Users (Hospitals, Clinics & Labs, Other Healthcare Facilities) and Region/Country
December 2019
399
About the Report
About the Report
Health care increasingly is subject to demands for better health and quality of life and limitations on the spending required to deliver these improvements. Molecular Diagnostics, aid in responding to such demands by enabling precise detection of health risks and disease at earlier stages and improving treatment and disease management, while diminishing subsequent health problems and their associated costs. Diagnostics serve a key role in the health value chain by influencing the quality of patient care, health outcomes, and downstream resource requirements. From consumer-friendly at-home pregnancy and glucose monitoring tests to more complex automated laboratory-based systems, these tests are often first-line health decision tools. While diagnostics comprise less than 5% of hospital costs and about 1.6% of all insurance costs, their findings influence as much as 60-70% of health care decision-making. The value of diagnostics accrues not only to clinicians and patients but to health care managers, third-party payers and quality assurance organizations that use diagnostic performance to measure and improve health care quality.
Diagnostics have evolved with an understanding of biological systems and disease, along with advances in science and technology. Emerging today are entirely new categories of diagnostics, based on the full continuum of care and personalized medicine approaches. With the potential to fundamentally alter clinical practice, these technologies are intended to match the right patient with the right treatment at the right time. As such products mature, clinicians and patients are expected to assess the risks and benefits of care options and customized health management strategies to optimize individual health and quality of life. Considering the increasing reliance on diagnostics in all phases of patient care, they afford substantial opportunities to improve quality and efficiency. Despite the value and potential of diagnostics, certain internal and external constraints, including regulatory, reimbursement, market, scientific/technical and societal issues, can inhibit the development, adoption and appropriate use of diagnostic products. Among all types of Molecular Diagnostics product type, reagents segment is expected to dominate the market, however, the market for instruments services segment is expected to grow at the highest CAGR of 7.12% over the forecast period owing to the recent advancements in IVD instruments, growth in demand for fully automated instruments in market, as they simplify the task and provide more accurate and reliable results. The molecular diagnostics has grown, due to advances in the chemistries and instrumentation, including automation, integration, throughput, and the ability to use the instrumentation in a random-access mode.
In terms of technique type; the Molecular Diagnostics market is bifurcated into Polymerase Chain Reaction (PCR), Transcription-Mediated Amplification (TMA), In Situ Hybridization & FISH, DNA Sequencing & Next-Generation Sequencing (NGS), Chips and Microarrays and Others. PCR is the most widely used technology in Molecular Diagnostics. The PCR occupied the largest share and is expected to maintain its dominance throughout the forecast period 2019-2025 owing to the increased usage and advancements in PCR techniques such as multiplex PCR. It is expected to grow considerably and DNA Sequencing & Next-Generation Sequencing is anticipated to grow at a CAGR of 5.73% and 8.64% respectively over the analyzed period owing to its increasing demand and nature of being cost-efficient. DNA Sequencing is expected to show the fastest growth over the forecast period owing to factors such as a possible decrease in cost and rise in the portability of DNA sequencers combined with the development of NGS techniques, providing high throughput analysis and sequencing of genomic data. There is tremendous market growth of molecular diagnostics because of the growing use of NGS and PCR technology. Industry growth is further propelled by increased access to healthcare services and rapidly increasing government investments. Moreover, increased awareness pertaining to the benefits of early diagnosis and high adoption rates for technologically advanced methods will also propel the molecular diagnostics market's growth. Furthermore, In Situ Hybridization (ISH) is projected to witness a substantial growth rate during the forecast period. An increase in the size of cancer affected the population and the need for early cancer diagnosis are some of the drivers of this segment.
The Molecular Diagnostics market is fragmented into various application types such as Microbiology, Virology, Hospital Acquired Infections (HAI), Genetic Testing, Oncology, Pharmacogenetics, Human Leukocytes Antigen (HLA), Blood Screening and others. Virology is anticipated to dominate this segment in 2025. However, the Oncology application type will rise with the highest CAGR during the forecast due to the rising trend. An increase in the incidence of cancer and the development of advanced cancer diagnostic tests, such as companion diagnostics, are some of the factors estimated to attribute to the high CAGR of the oncology segment over the forecast period. Companion diagnostics is based on the concept of personalized medicine and involves the identification of biomarker response in a population of patients with the same type of cancer. Moreover, the introduction of such advanced diagnostic technologies will prove to be cost-effective and will further boost the growth of the oncology segment. On the basis of the end-user analysis of the molecular diagnostics industry, the Hospitals segment contributed USD 3,450 million by revenue and is expected to grow with the highest CAGR of 5.43% over the forecast period through 2025. The hospitals dominate the market due to high procedure volume and extensive presence of ancillary support in terms of manpower and infrastructure. Many specialties currently have fully automated and advanced equipment, which produce results within minutes of loading the sample. Even the more 'hands-on' specialties like microbiology are gradually becoming more streamlined as machinery is created to decrease result time and allow researchers and pathologists to concentrate on results analysis and individual patient care.
Major companies in the global molecular diagnostics market are fragmented as Abbott Laboratories, Becton, Dickinson and Company, Biomerieux SA, Danaher Corporation, Hologic, Inc., Qiagen, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation and Thermo Fisher Scientific. These players are working endlessly to offer consumer a better and sustainable mobility service across the globe. Innovative product launch and expansion through the strategic partnership are foremost strategies adopted by the companies to garner a higher market share. Technological advancements and growing R&D initiatives are expected to drive industry growth. Products with superior technologies such as broader range application equipment and multitasking reagents will continue to find a deeper penetration in the molecular diagnostics market. New technologies will also bring greater effectiveness to current methods. Technologies such as nanotechnology are also likely to support the development of the molecular diagnostics field. The Molecular Diagnostics market is presently at its growing stage in India and is expected to capture a significant share in the In-Vitro Diagnostics market in the coming years. The Molecular Diagnostics market is becoming increasingly crowded. It is estimated that more than 100 companies compete in this market, although some are still in the development stage. It is worth noting that this crowded market exists even though there have been numerous acquisitions in this field to date. As an example, Qiagen has purchased several small and large molecular diagnostic companies over the last decade, including the 2018 acquisition of Spain based STAT-Dx for its sample-to answer POC platform. In 2016, Luminex purchased Nanosphere for its Verigene multiplex platform, and Danaher acquired Cepheid. Another notable example is bioMerieux's acquisition of BioFire in 2014 for US$ 450 million. The BioFire division with its unique high multiplex FilmArray product generated more than US$ 400 million in product sales in 2017. EAC's analysis reveals that nine companies controlled almost 76% of the US$ 6.6 billion MDx markets in 2017 (based on manufacturer's revenues). Nonetheless, numerous small companies continue to emerge and grow in this dynamic market.
The preceding figure gives the forecast value of the global Molecular Diagnostics Market from 2018 to 2025. The Global Molecular Diagnostics market generated revenue of US$ 6,242.6 million in 2018 and is expected to witness a CAGR growth of 6.3% during the forecast period 2019-2025, to reach a market size of US$ 9,546.2 million by 2025.
Products
Companies
Abbott Laboratories, Becton, Dickinson and Company, Biomerieux SA, Danaher Corporation, Hologic, Inc., Qiagen, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific
Table of Contents
Table of Contents
1. MARKET INTRODUCTION
1.1 Market Definition 21
1.2 Objective of the Study 21
1.3 Limitation 22
1.4 Stakeholders 22
1.5 Currency used in the Report 22
1.6 Scope of the Global Molecular Diagnostics Market Study 23
2. RESEARCH METHODOLOGY 24
2.1 Research Methodology for Global Molecular Diagnostics (MDx) Market Study 24
2.1.1 Main objective of the Global Molecular Diagnostics Market Study 25
3. COMPREHENSIVE ASSESSMENT OF THE VALUE OF DIAGNOSTIC TESTS 26
3.1 General Overview 26
3.2 Capturing the full spectrum of the value that a diagnostic test contributes 29
3.3 Ensuring that robust analyses underpin the value assessment 31
3.4 Accounting for variation in diagnostic test types in value assessment methods 32
3.5 Aligning on how to define and measure value drivers 34
3.5.1 Value Driver: Clinical Impact 34
3.5.2 Value Driver: Non-Clinical Patient Impact 36
3.5.3 Value Driver: Care Delivery Revenue and Cost Impact 37
3.5.4 Value Driver: Public/Population Impact 39
4. REFRAMING THE DIAGNOSTICS INDUSTRY 41
4.1 General Overview 41
5. EXECUTIVE SUMMARY 44
6. INDUSTRY PERFORMANCE 47
7. RISK MITIGATION 48
7.1 General Overview 48
7.2 Supply Chain 49
7.3 Risk Assessment 50
7.4 Bulk, Custom and Contract Manufacturing 51
5. MARKET OVERVIEW 52
5.1 Introduction of Molecular Diagnostics Market 52
5.1.1 Essential Components or Attributes of Diagnostics 54
5.1.2 Main Categories of Diagnostics 55
5.1.3 Settings of Use 57
5.2 Current and Future Use of Diagnostic Products 58
5.2.1 Primary Uses of Diagnostics 58
5.2.1.1 Predictive Applications/Screening/Early Disease Detection 59
5.2.1.2 Diagnostic 59
5.2.1.3 Secondary Risk Assessment-Prognostic 60
5.2.1.4 Drug Selection/Treatment Targeting 60
5.2.1.5 Disease/Condition Monitoring and Management 60
5.2.2 Molecular Diagnostics: Overview of Future Trends and Directions 60
5.2.2.1 Predict Disease Before Symptoms Appear 60
5.2.2.2 Predict Beneficial and Adverse Treatment Effects 61
5.2.2.3 Enable Personalized Real-Time Treatment and Disease Management Regimens 63
5.2.2.4 Facilitate Point-of-care and Near-patient Testing 64
5.2.2.5 Enable Home Testing 64
5.2.2.6 Public Health, Environmental, Bioterrorism Applications 65
5.2.2.7 Technology and Testing System Integration 66
5.2.3 The Importance of Molecular Diagnostics 67
5.2.4 Market Drivers 68
5.2.4.1 Increasing Prevalence of Chronic Diseases 68
5.2.4.2 Rising Geriatric Population 70
5.2.4.3 Increasing adoption of Point-of-Care Diagnosis 71
5.2.4.4 Technology Advancement in the In-Vitro Diagnostics 73
5.2.4.5 Advances in Genomics and Proteomics 74
5.2.5 Market Restraints 75
5.2.5.1 Unfavorable Reimbursement Policies for In-Vitro Diagnostics 75
5.2.5.2 High Prices of Molecular Diagnostics Tests 76
5.2.6 Market Opportunities 76
5.2.6.1 Increasing Support from Governments and Key Players 76
5.2.6.2 Growing Significance of Companion Diagnostics 78
5.2.7 Market Trends 80
5.2.7.1 Changing Reimbursement Models and Regulations 80
5.2.7.2 Investing in Unifying Technology 81
5.2.7.3 Consolidation and Automation of Labs 82
5.2.7.4 Shift to Data-Driven Healthcare 83
5.2.7.5 Consumer Lab Testing 83
5.2.7.6 Healthcare Convergence 84
6. REGULATIONS AND REIMBURSEMENT POLICY 86
6.1 Regulation 86
6.1.1 United States 86
6.1.1.1 Approval/Clearance of Molecular Diagnostic Instruments 86
6.1.1.2 Recommendations for Submissions for Molecular Diagnostic Instruments with Combined Functions 88
6.1.1.2.1 New Instruments 88
6.1.1.2.2 Existing Approved/Cleared Instruments 88
6.1.1.2.3 Submission Information, Labeling, and Marketing 88
6.1.1.2.4 Promotion and Labeling Issues 89
6.1.1.2.5 Software/Hardware Changes 89
6.1.1.2.6 Third-Party Assay Developers 90
6.1.1.2.7 MDR Reporting 90
6.2 Reimbursement 91
7. KEY MARKET INDICATORS 96
7.1 Demand Side Analysis 96
7.1.1 Some of the Key Facts about Aging Population 97
7.1.2 Health Conditions Associated with Aging 98
7.1.2.1 Some of the key facts about Cardiovascular Diseases (CVD) as per WHO 99
7.2 Supply Side Analysis 100
7.2.1 Product Launches 102
7.2.2 Partnership 108
7.2.3 Business Expansions and Investments 112
7.2.4 Merger and Acquisition 114
7.3 SWOT Analysis of Molecular Diagnostics 116
7.4 Value Chain Analysis of Molecular Diagnostics 117
8. MARKET INSIGHT BY PRODUCT 118
8.1 General Overview 118
8.1.1 Reagents 120
8.1.2 Instruments Services 126
9. MARKET INSIGHT BY TECHNIQUE 131
9.1 General Overview 131
9.1.1 Polymerase chain reaction (PCR) 133
9.1.2 Transcription-Mediated Amplification (TMA) 136
9.1.3 In Situ Hybridization & FISH 137
9.1.4 DNA Sequencing & Next-Generation Sequencing (NGS) 138
9.1.5 Case Study: Next Generation Sequencing for Clinical Diagnostics 139
9.1.6 Chips and Microarrays 142
9.1.7 Others 144
10. MARKET INSIGHT BY APPLICATION 146
10.1 General Overview 146
10.1.1 Microbiology 147
10.1.2 Virology 148
10.1.3 Hospital Acquired Infections (HAI) 153
10.1.4 Genetic Testing 155
10.1.5 Oncology 156
10.1.6 Pharmacogenetics 160
10.1.7 Human Leukocyte Antigen (HLA Testing) 161
10.1.8 Blood Screening 163
10.1.9 Others 164
11. MARKET INSIGHT BY END USER 166
11.1 General Overview 166
11.1.1 Hospitals 167
11.1.2 Clinics & Laboratory 168
11.1.3 Others 173
12. MARKET INSIGHT BY REGION 175
12.1 General Overview 175
12.2 North America MDx Market Insight 177
12.2.1 North America Molecular Diagnostics Market by Product 178
12.2.2 North America Molecular Diagnostics Market by Technique 178
12.2.3 North America Molecular Diagnostics Market by Application 179
12.2.4 North America Molecular Diagnostics Market by End Users 179
12.2.5 North America Molecular Diagnostics Market by Country 180
12.2.5.1 United States 180
12.2.5.1.1 Key Findings on Healthcare Spending in the US, 2017 181
12.2.5.1.2 US Health Spending by Type of Service or Product, 2017 181
12.2.5.1.3 Health Spending by Major Sources of Funds 182
12.2.5.1.4 United States Molecular Diagnostics Market by Product 184
12.2.5.1.5 United States Molecular Diagnostics Market by Technique 184
12.2.5.1.6 United States Molecular Diagnostics Market by Application 185
12.2.5.1.7 United States Molecular Diagnostics Market by End Users 185
12.2.5.2 Canada 186
12.2.5.2.1 Key Findings on Canada Healthcare Spending, 2018 187
12.2.5.2.2 Key Findings on Hospital sector Spending in Canada, 2017 188
12.2.5.2.3 Canada Molecular Diagnostics Market by Product 189
12.2.5.2.4 Canada Molecular Diagnostics Market by Technique 190
12.2.5.2.5 Canada Molecular Diagnostics Market by Application 190
12.2.5.2.6 Canada Molecular Diagnostics Market by End Users 191
12.2.5.3 Rest of North America 191
12.2.5.3.1 Rest of NA Molecular Diagnostics Market by Product 192
12.2.5.3.2 Rest of NA Molecular Diagnostics Market by Technique 193
12.2.5.3.3 Rest of NA Molecular Diagnostics Market by Application 193
12.2.5.3.4 Rest of NA Molecular Diagnostics Market by End Users 194
12.3 Europe Molecular Diagnostics Market Insight 194
12.3.1 Europe Molecular Diagnostics Market by Product 195
12.3.2 Europe Molecular Diagnostics Market by Technique 196
12.3.3 Europe Molecular Diagnostics Market by Application 196
12.3.4 Europe Molecular Diagnostics Market by End Users 197
12.3.5 Europe Molecular Diagnostics Market by Country 197
12.3.5.1 Germany 198
12.3.5.1.1 Germany Molecular Diagnostics Market by Product 199
12.3.5.1.2 Germany Molecular Diagnostics Market by Technique 200
12.3.5.1.3 Germany Molecular Diagnostics Market by Application 200
12.3.5.1.4 Germany Molecular Diagnostics Market by End Users 201
12.3.5.2 France 201
12.3.5.2.1 France Molecular Diagnostics Market by Product 202
12.3.5.2.2 France Molecular Diagnostics Market by Technique 203
12.3.5.2.3 France Molecular Diagnostics Market by Application 203
12.3.5.2.4 France Molecular Diagnostics Market by End Users 204
12.3.5.3 Spain 204
12.3.5.3.1 Spain Molecular Diagnostics Market by Product 206
12.3.5.3.2 Spain Molecular Diagnostics Market by Technique 206
12.3.5.3.3 Spain Molecular Diagnostics Market by Application 207
12.3.5.3.4 Spain Molecular Diagnostics Market by End Users 207
12.3.5.4 Italy 208
12.3.5.4.1 Italy Molecular Diagnostics Market by Product 209
12.3.5.4.2 Italy Molecular Diagnostics Market by Technique 209
12.3.5.4.3 Italy Molecular Diagnostics Market by Application 210
12.3.5.4.4 Italy Molecular Diagnostics Market by End Users 210
12.3.5.5 United Kingdom 211
12.3.5.5.1 United Kingdom Molecular Diagnostics Market by Product 213
12.3.5.5.2 United Kingdom Molecular Diagnostics Market by Technique 213
12.3.5.5.3 United Kingdom Molecular Diagnostics Market by Application 214
12.3.5.5.4 United Kingdom Molecular Diagnostics Market by End Users 214
12.3.5.6 Rest of Europe 215
12.3.5.6.1 Rest of Europe Molecular Diagnostics Market by Product 216
12.3.5.6.2 Rest of Europe Molecular Diagnostics Market by Technique 217
12.3.5.6.3 Rest of Europe Molecular Diagnostics Market by Application 217
12.3.5.6.4 Rest of Europe Molecular Diagnostics Market by End Users 218
12.4 Asia-Pacific Molecular Diagnostics Market Insight 218
12.4.1 Asia-Pacific Molecular Diagnostics Market by Product 219
12.4.2 Asia-Pacific Molecular Diagnostics Market by Technique 220
12.4.3 Asia-Pacific Molecular Diagnostics Market by Application 220
12.4.4 Asia-Pacific Molecular Diagnostics Market by End Users 221
12.4.5 Asia-Pacific Molecular Diagnostics Market by Country 221
12.4.5.1 China 222
12.4.5.1.1 China In-Vitro Diagnostics Services Market 223
12.4.5.1.2 China Molecular Diagnostics Market by Product 223
12.4.5.1.3 China Molecular Diagnostics Market by Technique 224
12.4.5.1.4 China Molecular Diagnostics Market by Application 224
12.4.5.1.5 China Molecular Diagnostics Market by End Users 225
12.4.5.2 India 225
12.4.5.2.1 India Molecular Diagnostics Market by Product 227
12.4.5.2.2 India Molecular Diagnostics Market by Technique 228
12.4.5.2.3 India Molecular Diagnostics Market by Application 228
12.4.5.2.4 India Molecular Diagnostics Market by End Users 229
12.4.5.3 Japan 229
12.4.5.3.1 Japan Molecular Diagnostics Market by Product 231
12.4.5.3.2 Japan Molecular Diagnostics Market by Technique 232
12.4.5.3.3 Japan Molecular Diagnostics Market by Application 232
12.4.5.3.4 Japan Molecular Diagnostics Market by End Users 233
12.4.5.4 Australia 233
12.4.5.4.1 Australia Molecular Diagnostics Market by Product 235
12.4.5.4.2 Australia Molecular Diagnostics Market by Technique 236
12.4.5.4.3 Australia Molecular Diagnostics Market by Application 236
12.4.5.4.4 Australia Molecular Diagnostics Market by End Users 237
12.4.5.5 Rest of APAC Market Insight 237
12.4.5.5.1 Rest of APAC Molecular Diagnostics Market by Product 239
12.4.5.5.2 Rest of APAC Molecular Diagnostics Market by Technique 239
12.4.5.5.3 Rest of APAC Molecular Diagnostics Market by Application 240
12.4.5.5.4 Rest of APAC Molecular Diagnostics Market by End Users 240
12.5 Rest of World Market Insight 241
12.5.1 Rest of World Molecular Diagnostics Market by Product 242
12.5.2 Rest of World Molecular Diagnostics Market by Technique 242
12.5.3 Rest of World Molecular Diagnostics Market by Application 243
12.5.4 Rest of World Molecular Diagnostics Market by End Users 243
12.5.5 Rest of World Molecular Diagnostics Market by Country 244
12.5.5.1 Brazil 244
12.5.5.1.1 Brazil Molecular Diagnostics Market by Product 246
12.5.5.1.2 Brazil Molecular Diagnostics Market by Technique 246
12.5.5.1.3 Brazil Molecular Diagnostics Market by Application 247
12.5.5.1.4 Brazil Molecular Diagnostics Market by End Users 247
12.5.5.2 Other Rest of World 248
12.5.5.2.1 Other Rest of World Molecular Diagnostics Market by Product 248
12.5.5.2.2 Other Rest of World Molecular Diagnostics Market by Technique 249
12.5.5.2.3 Other Rest of World Molecular Diagnostics Market by Application 249
12.5.5.2.4 Other Rest of World Molecular Diagnostics Market by End Users 250
13. COMPETITIVE SCENARIO 251
13.1 Porter s Five forces analysis 251
13.1.1 Bargaining Power of Suppliers 252
13.1.2 Bargaining Power of Buyers 252
13.1.3 Threat of New Entrants 253
13.1.4 Threat of Substitutes 254
13.1.5 Industry Rivalry 254
13.2 Market Share Analysis, by Company 255
13.2.1 Molecular Diagnostics Market Share Analysis by Company 2018 255
14. TOP COMPANY PROFILES 258
14.1 Abbott Laboratories 258
14.1.1 Key Facts 258
14.1.2 Business Description 258
14.1.3 Key Product/Services Offerings 259
14.1.4 Growth Strategy 259
14.1.5 SWOT Analysis 260
14.1.6 Key Financials 261
14.1.6.1 Revenue Split 262
14.1.7 Recent Developments 262
14.1.7.1 Product Launches 262
14.1.7.2 Partnership 263
14.1.7.3 Merger and Acquisition 263
14.2 Becton, Dickinson and Company 264
14.2.1 Key Facts 264
14.2.2 Business Description 264
14.2.3 Key Product/Services Offerings (AI Technology) 264
14.2.4 Growth Strategy 265
14.2.5 SWOT Analysis 266
14.2.6 Key Financials 267
14.2.6.1 Revenue Split 268
14.2.7 Recent Developments 268
14.2.7.1 Product Launches 268
14.2.7.2 Business Expansions and Investments 269
14.2.7.3 Merger & Acquisitions 270
14.3 Biomerieux SA 271
14.3.1 Key Facts 271
14.3.2 Business Description 271
14.3.3 Key Product/Services Offerings 272
14.3.4 Growth Strategy 272
14.3.5 SWOT Analysis 273
14.3.6 Key Financials 274
14.3.6.1 Revenue Split 275
14.3.7 Recent Developments 275
14.3.7.1 Product Launches 275
14.3.7.2 Partnerships 276
14.3.7.3 Mergers and Acquisitions 277
14.4 Hologic, Inc. 278
14.4.1 Key Facts 278
14.4.2 Business Description 278
14.4.3 Key Product/Services Offerings 279
14.4.4 Growth Strategy 281
14.4.5 SWOT Analysis 281
14.4.6 Key Financials 282
14.4.6.1 Revenue Split 283
14.4.7 Recent Developments 283
14.4.7.1 Product Launches 283
14.4.7.2 Partnerships 285
14.4.7.3 Business Expansion & Investment 286
14.4.7.4 Mergers and Acquisitions 286
14.5 Danaher Corporation 287
14.5.1 Key Facts 287
14.5.2 Business Description 287
14.5.3 Key Product/Services Offerings 287
14.5.4 Growth Strategy 288
14.5.5 SWOT Analysis 289
14.5.6 Key Financials 290
14.5.6.1 Revenue Split 291
14.5.7 Recent Developments 291
14.5.7.1 Merger and Acquisitions 291
14.6 Qiagen 292
14.6.1 Key Facts 292
14.6.2 Business Description 292
14.6.3 Key Product/Services Offerings 293
14.6.4 Growth Strategy 293
14.6.5 Key Milestones 294
14.6.6 SWOT Analysis 294
14.6.7 Key Financials 295
14.6.7.1 Revenue Split 296
14.6.8 Recent Developments 296
14.6.8.1 Product Launches 296
14.6.8.2 Partnerships 297
14.6.8.3 Business Expansions and Investment 299
14.6.8.4 Mergers and Acquisitions 300
14.7 Roche Holding AG 301
14.7.1 Key Facts 301
14.7.2 Business Description 301
14.7.3 Key Product/Services Offerings 302
14.7.4 Growth Strategy 302
14.7.5 SWOT Analysis 303
14.7.6 Key Financials 304
14.7.6.1 Revenue Split 305
14.7.7 Recent Developments 305
14.7.7.1 Product Launches 305
14.7.7.2 Partnership 307
14.7.7.3 Mergers and Acquisitions 307
14.8 Siemens Healthineers AG 308
14.8.1 Key Facts 308
14.8.2 Business Description 308
14.8.3 Key Product/Services Offerings 309
14.8.4 Growth Strategy 309
14.8.5 SWOT Analysis 310
14.8.6 Key Financials 311
14.8.6.1 Revenue Split 312
14.8.7 Recent Developments 312
14.8.7.1 Product Launches 312
14.8.7.2 Partnership 313
14.8.7.3 Business Expansion and Investment 313
14.8.7.4 Merger and Acquisitions 313
14.9 Thermo Fisher Scientific 314
14.9.1 Key Facts 314
14.9.2 Business Description 314
14.9.3 Key Product/Services Offerings 315
14.9.4 Growth Strategy 317
14.9.5 SWOT Analysis 317
14.9.6 Key Financials 318
14.9.6.1 Revenue Split 319
14.9.7 Recent Developments 319
14.9.7.1 Product Launch 319
14.9.7.2 Partnerships 322
14.9.7.3 Expansion and Investment 323
14.9.7.4 Merger and Acquisition 324
14.10 Sysmex Corporation 326
14.10.1 Key Facts 326
14.10.2 Business Description 326
14.10.3 Key Product/Services Offerings 326
14.10.4 Growth Strategy 327
14.10.5 SWOT Analysis 328
14.10.6 Key Financials 329
14.10.6.1 Revenue Split 330
14.10.7 Recent Developments 330
14.10.7.1 Product Launches 330
14.10.7.2 Partnership 331
14.10.7.3 Business Expansion & Investments 332
14.10.7.4 Merger and Acquisitions 333
List of Figure
FIG. 1 Scope of the Global Molecular Diagnostics Market Study 23
FIG. 2 Research Methodology for the Global Molecular Diagnostics Market Study 24
FIG. 3 Assessment Categories to Capture the Full Spectrum of Value 30
FIG. 4 Key Diagnostic Stakeholder Groups 31
FIG. 5 A Schematic: Approach for Effective Value Assessment 32
FIG. 6 Challenges Facing by Diagnostics Providers 41
FIG. 7 Ways to Win Diagnostics Value Game 42
FIG. 8 Ways to Survive in the Value Game 43
FIG. 9 Global Molecular Diagnostics Market Size by Value, 2018-2025 46
FIG. 10 Integrated Supply Chain Operations 49
FIG. 11 Key Risk categories for Supply Chain 50
FIG. 12 Capabilities to Support Risk Mitigation 51
FIG. 13 Primary Components of Diagnostic Processes 55
FIG. 14 Points of Entry in the Diagnostics Supply Chain 57
FIG. 15 Number of Labs in the United States 58
FIG. 16 Uses of Diagnostics Across the Health Care Continuum from Earliest Stages of Disease to Health Outcomes 59
FIG. 17 Timeline of key events related to Diagnostic and Laboratory-Developed Tests 67
FIG. 18 Prevalence of Chronic Disease in the US 69
FIG. 19 Global Leading Causes of Disability-Adjusted Life Year (DALY) per 100,000 population, 2000 and 2016 69
FIG. 20 Global population by broad age group, in 2017, 2030 and 2050 71
FIG. 21 New Approaches to Shaping Care-iSTAT Process 73
FIG. 22 Artificial Intelligence and In Vitro Diagnostics: Advancing Patient Care 74
FIG. 23 Companion Diagnostics Market: Most Common Disease Areas, North America 78
FIG. 24 Companion Diagnostics Market: Most Common Disease Areas, Europe 79
FIG. 25 Top Five Factors that Influence IVD Companies' Business Models 82
FIG. 26 Digital Health Step Process Globally 83
FIG. 27 IVD Market Lab Testing Changes, US, 2015 84
FIG. 28 Internal Convergence Model 85
FIG. 29 Digital Health and IVD Convergence Model-Diabetes 85
FIG. 30 Effects of Limitations to Reimbursement Systems. Budget Silos and Counter Incentives of Tariff Payment Systems 93
FIG. 31 Adoption of Molecular Diagnostics 96
FIG. 32 Number and Distribution of Persons Aged 60 Years or Over by Region, in 2017 and 2050 (in Millions) 97
FIG. 33 Global Population over 60 years and above (in Billion) 98
FIG. 34 Global deaths per 100,000; in 2000 and 2017 99
FIG. 35 Factors Driving the Demand of Molecular Diagnostics 100
FIG. 36 Impact of Early Supplier Involvement 101
FIG. 37 Molecular Diagnostics Market SWOT Analysis 116
FIG. 38 Molecular Diagnostics diagnostics Value Chain 117
FIG. 39 Global Molecular Diagnostics Market, By Product 2018-2025 (%) 119
FIG. 40 Global Molecular Diagnostic Market Size, by Product, 2018-25 (USD Mn) 120
FIG. 41 Molecular Diagnostics Reagents 121
FIG. 42 Global Molecular Diagnostic Reagents Market Size, by Region, 2018-25 (USD Mn) 126
FIG. 43 WHO classification digital health services 128
FIG. 44 Global Molecular Diagnostic Instruments Services Market Size, by Region, 2018-25 (USD Mn) 130
FIG. 45 Molecular toolkit for Diagnostics 132
FIG. 46 Global Molecular Diagnostics Market Share by Technique, 2018- 2025 (%) 132
FIG. 47 Global Molecular Diagnostics Market Size by Technique, 2018- 2025 (USD Mn) 133
FIG. 48 Overview of technologies used for detection and profiling of Nucleic Acid Sequence Variations 134
FIG. 49 Global Molecular Diagnostics Polymerase Chain Reaction Market Size, by Region, 2018-25 (USD Mn) 136
FIG. 50 Global Molecular Diagnostics Transcription-Mediated Amplification Market Size, by Region, 2018-25 (USD Mn) 137
FIG. 51 Global Molecular Diagnostics In Situ Hybridization & FISH Market Size, by Region, 2018-25 (USD Mn) 138
FIG. 52 Diagnostic Yield among Medical Specialities utilizing NGS 140
FIG. 53 Development Flowchart of an NGS-based Clinical Diagnostics Test 141
FIG. 54 Global Molecular Diagnostics DNA Sequencing & NGS Market Size, by Region, 2018-25 (USD Mn) 142
FIG. 55 Global Molecular Diagnostics Chips and Microarrays Market Size, by Region, 2018-25 (USD Mn) 144
FIG. 56 Global Molecular Diagnostics Other Techniques Market Size, by Region, 2018-25 (USD Mn) 145
FIG. 57 The Leading Causes of Death Around the Globe, 2016 (in million) 146
FIG. 58 Global Molecular Diagnostics Market Share by Application, 2018- 2025 (%) 146
FIG. 59 Global Microbiology Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 148
FIG. 60 People Living with HIV by region, 2018 (in Million) 152
FIG. 61 Global Virology Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 152
FIG. 62 Global HAI Testing Market 153
FIG. 63 Global Hospital Acquired Infections (HAI) Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 154
FIG. 64 Global Genetic Testing Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 156
FIG. 65 Deaths Due to Cancers in 2018 (in million) 157
FIG. 66 Global Oncology Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 159
FIG. 67 Global Pharmacogenetics Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 161
FIG. 68 Global MDx Blood Screening Market 162
FIG. 69 Global Human Leukocytes Antigen (HLA) Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 162
FIG. 70 Global Blood Screening Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 164
FIG. 71 Global Other Applications Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 165
FIG. 72 Global Molecular Diagnostics Market Share, by End User, 2018 & 2025 (%) 166
FIG. 73 Global Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 166
FIG. 74 Global Hospitals Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 167
FIG. 75 Types of Laboratories, United States, 2017 168
FIG. 76 Global Clinics & Labs Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 173
FIG. 77 Global Other End Users Molecular Diagnostics Market Size, by Region, 2018-25 (USD Mn) 174
FIG. 78 World Population Pyramid Transition, 2050-2100 (Billion) 175
FIG. 79 Number of Persons aged 60 years or older (Million) 176
FIG. 80 Global Molecular Diagnostics Market Share by Region 2018-2025 (%) 176
FIG. 81 Global Molecular Diagnostics Market Size by Region, 2019-25 (USD Mn) 177
FIG. 82 North America Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 178
FIG. 83 North America Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 178
FIG. 84 North America Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 179
FIG. 85 North America Molecular Diagnostics Market Size, by Country, 2018-25 (USD Mn) 180
FIG. 86 Leading Causes of Death in the United States, per 100,000 Population (2016 & 2017) 181
FIG. 87 US Health Spending by Type of Service or Product, 2017 183
FIG. 88 United States Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 184
FIG. 89 United States Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 184
FIG. 90 United States Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 185
FIG. 91 Drivers Escalating the Growth of Molecular Diagnostics Market in Canada 186
FIG. 92 Prevalence of Chronic Diseases Among Canadian Adults, 2019 187
FIG. 93 Canada Health Spending by Sources of Funds, 2017 188
FIG. 94 Canadian Hospital Spending by Type and Function, 2018 (%) 189
FIG. 95 Canada Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 189
FIG. 96 Canada Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 190
FIG. 97 Canada Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 191
FIG. 98 Rest of NA Population ages 65 and above, by Country (% of total), 2018 191
FIG. 99 Proportional Mortality in 2017 192
FIG. 100 Rest of NA Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 192
FIG. 101 Rest of NA Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 193
FIG. 102 Rest of NA Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 194
FIG. 103 Number of Death Caused by Cancer in Europe (2015) by Country (Units) 195
FIG. 104 Europe Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 195
FIG. 105 Europe Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 196
FIG. 106 Europe Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 197
FIG. 107 Europe Molecular Diagnostics Market Size, by Country, 2018-25 (USD Mn) 197
FIG. 108 Proportional Mortality in Germany, by Percentage 198
FIG. 109 Germany Health Spending 199
FIG. 110 Germany Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 199
FIG. 111 Germany Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 200
FIG. 112 Germany Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 201
FIG. 113 Proportional mortality in France by Disease Type (%) 202
FIG. 114 France Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 202
FIG. 115 France Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 203
FIG. 116 France Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 204
FIG. 117 Major Causes of Death in Spain 2018 by Percentage (%) 205
FIG. 118 Spain Government Health Expenditure, 2010-2018 205
FIG. 119 Spain Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 206
FIG. 120 Spain Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 206
FIG. 121 Spain Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 207
FIG. 122 Causes of Death in Italy by Gender, (%) 2014 208
FIG. 123 Italy Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 209
FIG. 124 Italy Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 209
FIG. 125 Italy Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 210
FIG. 126 The population of the UK Recorded Over 65 Years in 2015, 2025, 2035 & 2045 (%) 211
FIG. 127 Causes of Death in England in Males and Females in 2015, by Percentage (%) 212
FIG. 128 UK Government Health Expenditure, 2013-2017 212
FIG. 129 United Kingdom Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 213
FIG. 130 United Kingdom Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 213
FIG. 131 United Kingdom Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 214
FIG. 132 Rest of Europe % of the population over 65 years old by Country, 2017 215
FIG. 133 Health Expenditure Per Capita by Country, 2017 (or nearest year) 216
FIG. 134 Rest of Europe Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 216
FIG. 135 Rest of Europe Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 217
FIG. 136 Rest of Europe Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 218
FIG. 137 Role of Laboratory Services in Asia Pacific Region 219
FIG. 138 Asia-Pacific Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 219
FIG. 139 Asia-Pacific Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 220
FIG. 140 Asia-Pacific Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 221
FIG. 141 Asia-Pacific Molecular Diagnostics Market Size, by Country, 2018-25 (USD Mn) 221
FIG. 142 China In-Vitro Diagnostics Services Market Size 2020-2025 (Unit Billion) 223
FIG. 143 China Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 223
FIG. 144 China Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 224
FIG. 145 China Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 225
FIG. 146 India Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 227
FIG. 147 India Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 228
FIG. 148 India Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 229
FIG. 149 Japanese Population Comparison by Age Group, 2018 & Future (% of the total population) 230
FIG. 150 Japanese Current & Future Per Capita Healthcare Spending by Source of Fund 2016 and 2050 (USD ) 231
FIG. 151 Japan Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 231
FIG. 152 Japan Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 232
FIG. 153 Japan Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 233
FIG. 154 Total Health Expenses, USD Million 235
FIG. 155 Australia Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 235
FIG. 156 Australia Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 236
FIG. 157 Australia Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 237
FIG. 158 Rest of APAC Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 239
FIG. 159 Rest of APAC Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 239
FIG. 160 Rest of APAC Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 240
FIG. 161 New Cancer Cases in Egypt, 2018 (%) 241
FIG. 162 Rest of World Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 242
FIG. 163 Rest of World Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 242
FIG. 164 Rest of World Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 243
FIG. 165 Rest of World Molecular Diagnostics Market Size, by Country, 2018-25 (USD Mn) 244
FIG. 166 Brazilian Healthcare Sector Map 245
FIG. 167 Current health expenditure (% of GDP)-Brazil 245
FIG. 168 Brazil Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 246
FIG. 169 Brazil Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 246
FIG. 170 Brazil Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 247
FIG. 171 Other Rest of World Molecular Diagnostics Market by Product, 2018-2025 (USD Mn) 248
FIG. 172 Other Rest of World Molecular Diagnostics Market Size, by Technique, 2018-25 (USD Mn) 249
FIG. 173 Other Rest of World Molecular Diagnostics Market Size, by End-Users, 2018-25 (USD Mn) 250
FIG. 174 Molecular Diagnostics Market: Porter's Five Forces Analysis 251
FIG. 175 Molecular Diagnostics Market Share Analysis by Company 2018 255
FIG. 176 Abbott laboratories Solutions for Diagnostics 259
FIG. 177 Abbott laboratories SWOT Analysis 260
FIG. 178 Key Financials of Abbott Laboratories 261
FIG. 179 Abbott Laboratories Revenue Split, 2018 262
FIG. 180 Becton, Dickinson and Company Q3 FY19 Financial Results 265
FIG. 181 Becton, Dickinson and Company SWOT Analysis 266
FIG. 182 Key Financials of Becton, Dickinson and Company 267
FIG. 183 Becton, Dickinson and Company Revenue Split, 2018 268
FIG. 184 Biomerieux SA, Vision 2020 Objectives and Results at End of 2018 273
FIG. 185 Biomerieux SA, SWOT Analysis 273
FIG. 186 Key Financials of Biomerieux SA 274
FIG. 187 Biomerieux SA, Revenue Split, 2018 (%) 275
FIG. 188 Timeline of Hologic, Inc. 279
FIG. 189 Hologic, Inc., SWOT Analysis 281
FIG. 190 Key Financials of Hologic, Inc. 282
FIG. 191 Hologic, Inc., Revenue Split, 2018 283
FIG. 192 Danaher Corporation, Science & Technology Portfolio 288
FIG. 193 Danaher Corporation SWOT Analysis 289
FIG. 194 Key Financials of Danaher Corporation 290
FIG. 195 Danaher Corporation Revenue Split by Segment, 2018 291
FIG. 196 Qiagen Milestones 294
FIG. 197 Qiagen., SWOT Analysis 294
FIG. 198 Key Financials of Qiagen 295
FIG. 199 Qiagen., Revenue Split, 2018 296
FIG. 200 Roche, Top-selling Diagnostics Product Portfolios in 2018 (CHF millions) 302
FIG. 201 Roche Strategy 303
FIG. 202 Roche SWOT Analysis 303
FIG. 203 Key Financials of Roche 304
FIG. 204 Roche Revenue Split, 2017 305
FIG. 205 Siemens Healthineers AG, Value Creation 309
FIG. 206 Siemens Healthineers AG SWOT Analysis 310
FIG. 207 Key Financials of Siemens Healthineers AG 311
FIG. 208 Siemens Healthineers AG, Revenue Split, 2018 312
FIG. 209 Thermo Fisher Scientific, Products Segment 315
FIG. 210 Thermo Fisher Scientific, SWOT Analysis 317
FIG. 211 Key Financials of Thermo Fisher Scientific 318
FIG. 212 Thermo Fisher Scientific, Revenue Split, 2018 (%) 319
FIG. 213 Sysmex Corporation, SWOT Analysis 327
FIG. 214 Sysmex Corporation, SWOT Analysis 328
FIG. 215 Key Financials of Sysmex Corporation 329
FIG. 216 Sysmex Corporation, Revenue Split, 2018 (%) 330
List of Table
TABLE 1 Principles for Effective Value Assessments 28
TABLE 2 Considerations in Demonstrating Value by Diagnostic Test Type 33
TABLE 3 Value Driver: Clinical Impact 34
TABLE 4 Value Driver: Non-Clinical Patient Impact 36
TABLE 5 Value Driver: Care Delivery Revenue and Cost Impact 38
TABLE 6 Value Driver: Public/Population Impact 39
TABLE 7 Risk from Raw Material Supply and In-House Manufacturing Capabilities of MDx Manufacturers 48
TABLE 8 Examples of Molecular Diagnostics across the Continuum of Care 53
TABLE 9 Categories and Examples of Diagnostic Products 56
TABLE 10 Rapidly Expanding Areas of Scientific Inquiry 61
TABLE 11 Number and distribution of persons aged 60 years or over by region, in 2017 and 2050 71
TABLE 12 Presently Used Proteomics Tools in Diseases Diagnostics 75
TABLE 13 Oncology CDx Market: Selected Tests Resulting from Partnerships, U.S., 2017 79
TABLE 14 MDx Market Regulatory Analysis, Selected Regions 81
TABLE 15 CEN/TS and ISO standards on the pre-examination process for Molecular Diagnostics that have emerged from SPIDIA 91
TABLE 16 Product Launches 102
TABLE 17 Partnership 108
TABLE 18 Business Expansions and Investments 112
TABLE 19 Merger and Acquisition 114
TABLE 20 Products List for In-Vitro Diagnostics Reagents 124
TABLE 21 IVD Ancillary Reagents 125
TABLE 22 IVD Market Regulatory Analysis, Selected Regions 127
TABLE 23 Overview of Next-Generation Sequencing Technologies 139
TABLE 24 Microarrays and Applications 143
TABLE 25 Global Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 147
TABLE 26 Standardised Molecular Protocols in Diagnostic Virology 149
TABLE 27 Examples of Molecular Diagnostics in Cancer 157
TABLE 28 General Molecular Diagnostics for Primary Health Care 169
TABLE 29 General Molecular Diagnostics for health care facilities with clinical laboratories 170
TABLE 30 Countries with Shift in Average Life Expectancies in 2030 175
TABLE 31 North America Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 179
TABLE 32 United States Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 185
TABLE 33 Canada Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 190
TABLE 34 Rest of NA Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 193
TABLE 35 Europe Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 196
TABLE 36 Germany Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 200
TABLE 37 France Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 203
TABLE 38 Spain Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 207
TABLE 39 Italy Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 210
TABLE 40 United Kingdom Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 214
TABLE 41 Rest of Europe Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 217
TABLE 42 Asia-Pacific Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 220
TABLE 43 China Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 224
TABLE 44 India Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 228
TABLE 45 Japan Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 232
TABLE 46 Australia, Total Health Expenses, USD Million 235
TABLE 47 Australia Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 236
TABLE 48 Rest of APAC Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 240
TABLE 49 Rest of World Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 243
TABLE 50 Brazil Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 247
TABLE 51 Other Rest of World Molecular Diagnostics Market Size, by Application, 2018-25 (USD Mn) 249
TABLE 52 Abbott Laboratories Key Facts 258
TABLE 53 Product segmentation of Abbott Laboratories 259
TABLE 54 Abbott laboratories Growth Strategy 259
TABLE 55 Abbott Laboratories, Inc. Product Launches 262
TABLE 56 Abbott Laboratories, Inc. Partnership 263
TABLE 57 Abbott Laboratories, Inc. Merger and Acquisition 263
TABLE 58 Becton, Dickinson and Company Key Facts 264
TABLE 59 Becton, Dickinson and Company Growth Strategy 264
TABLE 60 Becton, Dickinson and Company Growth Strategy 265
TABLE 61 Becton, Dickinson and Company Product Launches 268
TABLE 62 Becton, Dickinson and Company Business Expansions and Investments 269
TABLE 63 Becton, Dickinson and Company Merger & Acquisitions 270
TABLE 64 Biomerieux SA Key Facts 271
TABLE 65 Product segmentation of Biomerieux SA 272
TABLE 66 Biomerieux SA Growth Strategy 272
TABLE 67 Biomerieux SA Product Launches 275
TABLE 68 Biomerieux SA Partnerships 276
TABLE 69 Biomerieux SA Mergers and Acquisitions 277
TABLE 70 Hologic, Inc. Key Facts 278
TABLE 71 Hologic, Inc. Ownership Structure 278
TABLE 72 Product segmentation of Hologic, Inc. 279
TABLE 73 Hologic, Inc. Growth Strategy 281
TABLE 74 Hologic, Inc. Product Launches 283
TABLE 75 Hologic, Inc. Partnerships 285
TABLE 76 Hologic, Inc. Business Expansion & Investment 286
TABLE 77 Hologic, Inc. Merger and Acquisitions 286
TABLE 78 Danaher Corporation Key Facts 287
TABLE 79 Product Segmentation of Danaher Corporation 287
TABLE 80 Danaher Corporation Growth Strategy 288
TABLE 81 Danaher Corporation Merger and Acquisitions 291
TABLE 82 Qiagen Key Facts 292
TABLE 83 Qiagen. Ownership Structure 292
TABLE 84 Product Segmentation of Qiagen 293
TABLE 85 Qiagen Growth Strategy 293
TABLE 86 Qiagen Product Launches 296
TABLE 90 Roche Key Facts 301
TABLE 91 The product segmentation of Roche 302
TABLE 92 Roche Growth Strategy 302
TABLE 93 Roche Product Launches 305
TABLE 94 Roche Partnership 307
TABLE 95 Roche Mergers and Acquisitions 307
TABLE 96 Siemens Healthineers AG Key Facts 308
TABLE 97 Product Segmentation of Siemens Healthineers AG 309
TABLE 98 Siemens Healthineers AG Growth Strategy 309
TABLE 99 Siemens Healthineers AG Product Launches 312
TABLE 100 Siemens Healthineers AG Partnership 313
TABLE 101 Siemens Healthineers AG Business Expansion and Investment 313
TABLE 102 Siemens Healthineers AG Merger and Acquisitions 313
TABLE 103 Thermo Fisher Scientific Key Facts 314
TABLE 104 Product Segmentation of Thermo Fisher Scientific 315
TABLE 105 Thermo Fisher Scientific Growth Strategy 317
TABLE 106 Thermo Fisher Scientific Product Launch 319
TABLE 107 Thermo Fisher Scientific Partnerships 322
TABLE 108 Thermo Fisher Scientific Business Expansion and Investments 323
TABLE 109 Thermo Fisher Scientific Merger and Acquisition 324
TABLE 110 Sysmex Corporation Key Facts 326
TABLE 111 Product segmentation of Sysmex Corporation 326
TABLE 112 Sysmex Corporation Growth Strategy 327
TABLE 113 Sysmex Corporation Product Launches 330
TABLE 114 Sysmex Corporation Partnership 331
TABLE 115 Sysmex Corporation Business Expansion & Investments 332
TABLE 116 Sysmex Corporation Merger and Acquisitions 333
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.